Trials / Terminated
TerminatedNCT04493424
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
An Open-label, Long Term Safety Trial of Spesolimab Treatment in Patients With Palmoplantar Pustulosis (PPP) Who Have Completed Previous BI Spesolimab Trials
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab. Participants who benefited from spesolimab treatment in the previous studies can join this study. The purpose of this study is to find out how safe spesolimab is and whether it helps people with palmoplantar pustulosis in the long-term. Participants are in this study for up to 5 years. During this time they visit the study site every month to get spesolimab injections under the skin. At study visits, doctors check the severity of participants' palmoplantar pustulosis and collect information on any health problems of the participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spesolimab | Spesolimab |
Timeline
- Start date
- 2020-09-04
- Primary completion
- 2023-01-16
- Completion
- 2023-05-15
- First posted
- 2020-07-30
- Last updated
- 2025-10-20
- Results posted
- 2024-03-20
Locations
66 sites across 14 countries: United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Japan, Poland, Russia, South Korea, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04493424. Inclusion in this directory is not an endorsement.